Shopping Cart
Remove All
Your shopping cart is currently empty
JNJ-42226314 is a highly selective non-covalent monoacylglycerol lipase (MAGL) inhibitor with anti-injury effects.JNJ-42226314 shows efficacy via endogenous cannabinoid-2-acryloylglycerol (2-AG) in models of neuropathic pain and inflammatory pain.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 5 mg | $113 | In Stock | In Stock | |
| 10 mg | $183 | In Stock | In Stock | |
| 25 mg | $369 | In Stock | In Stock | |
| 50 mg | $595 | In Stock | In Stock | |
| 100 mg | $953 | - | In Stock | |
| 500 mg | $1,880 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $123 | In Stock | In Stock |
| Description | JNJ-42226314 is a highly selective non-covalent monoacylglycerol lipase (MAGL) inhibitor with anti-injury effects.JNJ-42226314 shows efficacy via endogenous cannabinoid-2-acryloylglycerol (2-AG) in models of neuropathic pain and inflammatory pain. |
| In vitro | After treatment with PF-3845 ( 1 or 10 μM ), JZL-184 ( 1 or 10 μM ), JNJ-42226314 ( 1 or 10 μM ) or carrier ( DMSO ), JNJ-42226314 was selectively analyzed by competitive ABPP. The results showed that JNJ-42226314 had high selectivity for MAGL [1]. |
| In vivo | In male C57Bl/6 mice weighing 20-30g and male Sprague-Dawley rats weighing 300-400g, treatment with JNJ-42226314 (3 mg/kg and 30 mg/kg; i.p.; 120 min) dose-dependently elevated hippocampal 2-AG levels in vivo[1]. |
| Molecular Weight | 489.56 |
| Formula | C26H24FN5O2S |
| Cas No. | 1252765-13-1 |
| Smiles | Fc1ccc(cc1)-n1ccc2cc(ccc12)C(=O)N1CC(C1)N1CCN(CC1)C(=O)c1nccs1 |
| Relative Density. | 1.44 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (204.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.21 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.